ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.

Sponsored by: Shionogi
Information provided by: Shionogi
ClinicalTrials.gov Identifier: NCT00078390
  Purpose

A study to measure the safety and effectiveness of S-3304 when given in combination with conventional chemo-radiation therapy in patients with locally advanced non-small cell lung cancer.


Condition Intervention Phase
Non Small Cell Lung Cancer
Lung Cancer
Stage IIIA Non Small Cell Lung Cancer
Stage IIIB Non Small Cell Lung Cancer
Drug: S-3304
Phase I
Phase II

MedlinePlus related topics:   Cancer    Lung Cancer   

Drug Information available for:   Collagenase    S 3304   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer.

Further study details as provided by Shionogi:

Estimated Enrollment:   90
Study Start Date:   February 2003

Detailed Description:

A two part study to evaluate the safety and efficacy of S-3304 in combination with standard therapy in patients with locally advanced non-small cell lung cancer. The first part of the study is a Phase I design to evaluate the maximum tolerated dose of S-3304 when given in combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for further evaluation. The second part of the study is a randomized Phase II design to evaluate the efficacy of recommended S-3304 dose in combination with chemo-radiation.

  Eligibility
Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

INCLUSION CRITERIA

  • newly diagnosed non-small cell lung cancer of stage IIIA non-resectable or of stage IIIB without pleural effusion
  • ECOG performance status 0-1
  • adequate organ function
  • clinically indicated and able to receive conventional chemoradiation therapy

EXCLUSION CRITERIA

  • patients with prior history of cancer, other than basal cell carcinoma after appropriate treatment, or prior systemic chemotherapy treatment
  • patients with other serious intercurrent illness including HIV/AIDS, or contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00078390

Locations
United States, California
Scripps Cancer Institute    
      La Jolla, California, United States, 92037
United States, District of Columbia
Lombardi Cancer Center    
      Washington D.C., District of Columbia, United States, 20007
United States, Kansas
University of Kansas Cancer Center    
      Kansas City, Kansas, United States, 66160
United States, New Jersey
VA Medical Center-East Orange (study available to veterans only)    
      East Orange, New Jersey, United States, 07108
United States, Ohio
The Cleveland Clinic    
      Cleveland, Ohio, United States, 44195

Sponsors and Collaborators
Shionogi
  More Information


Study ID Numbers:   0207P1421
First Received:   February 24, 2004
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00078390
Health Authority:   United States: Food and Drug Administration

Keywords provided by Shionogi:
Lung cancer  
Lung carcinoma  
Non small cell lung cancer  
Stage IIIA non small cell lung cancer  
Stage IIIB non small cell lung cancer  
NSCLC  
Stage III  
chemotherapy  
radiation
chemoradiation
matrix metalloproteinases
neovascularization
antiangiogenesis
type IV collagenases
Unresectable locally advanced non-small cell lung cancer

Study placed in the following topic categories:
Thoracic Neoplasms
Non-small cell lung cancer
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases
Neovascularization, Pathologic
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers